As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia ... be used concomitantly with intravenous immunoglobulin and plasma exchange ...

MG-ADL scores improved, indicating enhanced daily functioning for patients with myasthenia gravis. Limitations include potential coding errors, selection biases, and missing clinical data ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

flare-ups of intestinal diseases, such as ulcerative colitis flare-ups of nervous system disorders, such as multiple sclerosis or myasthenia gravis certain leukemias and lymphomas, which are blood ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

In this article we will help you to know more about the infusion therapy, about its process, precautions to be taken care ...

Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

The global peripheral intravenous catheter market is on a strong growth trajectory, projected to more than double in size over the next decade. According to recent market insights, the market is ...